WHO ICTRP trial
A phase IIa randomized, placebo controlled, double blinded study to evaluate the…
NL-OMON46133 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON46133 |
|---|---|
| Public title | A phase IIa randomized, placebo controlled, double blinded study to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. |
| Scientific title | A phase IIa randomized, placebo controlled, double blinded study to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. - iHIVARNA phase IIa study |
| Primary sponsor | Erasmus MC, Universitair Medisch Centrum Rotterdam |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | The Netherlands |
| Conditions | AIDS HIV infection;10021460;10047438;AIDS;HIV infection |
| Interventions | One group (n=40) receives the HIVACAT TriMix (300 microgram TriMix + 900 microgram HIVACAT-T) vaccine intranodally on three occasions with a two-week interval. One control group (n=15) receives TriMix only (300 microgram TriMix) and one… |
| Registration date | Jun 21, 2017 |
| Target size | 14 |
| Secondary IDs | 2016-002724-83;NCT02888756;NL57593.000.16 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: